The FDA has approved various GLP-1 receptor agonists for different indications, including glycemic control in type 2 diabetes and chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity
North Carolina Medicaid ended coverage of GLP-1s for obesity last month, citing shortfalls in state funding
Conditions we treat, but not inclusive: Allergies Common cold Skin conditions End stage renal disease Mental health Diabetes Osteoarthritis Anemia Arteriosclerosis Asthma COPD Hypertension Kidney diseases Other chronic conditions Reviews and ratings Summary The patient rating score is an average of all responses to an independent patient satisfaction survey administered by Qualtrics and patient feedback submitted via public review sites
During the October raid, MHRA officers had confiscated tens of thousands of empty pens ready to be filled, raw chemical ingredients, and more than 2,000 unlicensed retatrutide and tirzepatide branded Alluvi pens
FDA approved the first generic drug containing liraglutide in December 2024
The impact of obesity on disease activity and treatment response in rheumatoid arthritis